User: Guest  Login
Document type:
journal article 
Author(s):
Stuve, O, O; Hartung, H P, HP; Freedman, M, M; Li, D, D; Hemmer, B, B; Kappos, L, L; Rieckmann, P, P; Montalban, X, X; Ziemssen, T, T; Selmaj, K, K 
Title:
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. 
Abstract:
In the adaptive dose-ranging, 6- or 3-month BOLD study in patients with relapsing-remitting multiple sclerosis, once-daily siponimod (BAF312) showed dose-dependent reduction of combined unique active lesion number and annualized relapse rate (ARR); near-maximal effects were observed at 2mg. Here, we report the efficacy findings of first 12 months of the extension (representing>18 or 15 months of total treatment).Patients either continued on siponimod doses assigned in the core phase or were re-...    »
 
Journal title abbreviation:
Mult Scler Relat Disord 
Year:
2014 
Journal volume:
Journal issue:
Pages contribution:
754-5 
Language:
eng 
Print-ISSN:
2211-0348 
TUM Institution:
Neurologische Klinik und Poliklinik